Since the sequencing of the human genome, recent efforts in cancer drug target discovery have focused more on the identification of novel functions of known genes and the development of more appropriate tumor models. In the present study, we investigated in vitro transformed human adult mesenchymal stem cells (MSC) to identify novel candidate cancer drug targets by analyzing the transcriptional profile of known enzymes compared with non-transformed MSC. The identified enzymes were compared with published cancer gene expression data sets. Surprisingly, the majority of up-regulated enzymes are already known cancer drug targets or act within known druggable pathways. Only three enzymes (RNASEH2A, ADARB1, and PPAP2C) are potentially novel targets that are up-regulated in transformed MSC and expressed in numerous carcinomas and sarcomas. We confirmed the overexpression of RNASEH2A, PPAP2C, and ADARB1 in transformed MSC, transformed fibroblasts, and cancer cell lines MCF7, SK-LMS1, MG63, and U2OS. In functional assays, we show that small interfering RNA knockdown of RNASEH2A inhibits anchorage-independent growth but does not alter in vitro proliferation of cancer cell lines, normal MSC, or normal fibroblasts. Knockdown of PPAP2C impaired anchorage-dependent in vitro growth of cancer cell lines and impaired the in vitro growth of primary MSC but not differentiated human fibroblasts. We show that the knockdown of PPAP2C decreases cell proliferation by delaying entry into S phase of the cell cycle and is transcriptionally regulated by p53. These in vitro data validate PPAP2C and RNASEH2A as putative cancer targets and endorse this in silico approach for identifying novel candidates.
Introduction
According to the Food and Drug Administration, the cost of development for each new anticancer drug ranges from 800 million to 2 billion U.S. dollars (1) . It is estimated that only one in five drugs that enter phase I trials will reach U.S. regulatory approval; more importantly, half of drugs that enter the expensive phase III stage will not reach authorization (1) . The reasons for this high attrition rate are numerous, including issues of on-target and off-target safety concerns, particularly failure in the biological hypotheses driving the target (2) . Much of the recent efforts in target discovery have therefore focused on identification of novel disease relevant targets with a reduced probability of subsequent failure by improving early validation employing more suitable cancer models (2) .
There have been numerous attempts of in silico prediction of cancer drug targets including structural analyses of all known proteins to define ''the druggable genome,'' which converges on 2,000 to 3,000 targets that contain protein folds that are amenable to drug-like small chemical compounds (3, 4) . Statistical approaches have also been used to define 250 potentially successful cancer relevant targets of which 60 to 70 are currently being actively investigated (5) . However, the druggable genome is a ''moving target'' with protein modeling algorithms becoming more sophisticated, more hypothetical proteins being characterized allowing better annotations, and a changing perception of what classes of proteins can be targeted (4) . The largest categories of current drug targets are G protein-coupled receptors, ion channels, and various classes of enzymes (e.g., protein kinases; ref. 4) . Recent advances, including antisense delivery, small interfering RNA (siRNA) knockdown, and small-molecule carriers, may extend the range of proteins that could be targeted (6, 7) .
Recent studies have taken a reverse genomics approach to identify potential drug targets by screening short hairpin RNA (shRNA) libraries in cancer cell lines and assaying for genes required for proliferation (8, 9) . This approach has revealed a larger number of genes required by normal cells for proliferation and substantially less in cancer cells, reflecting the ability of cancer cells to evade growthinhibitory cues (9) . This work defines ''non-oncogene addiction'' genes, which are required by cancer cells to proliferate but are not required for normal cell proliferation (10) .
The cancer stem cell hypothesis suggests that tumors derive from a subpopulation of multipotent stem cells, which continually renew and sustain the malignant growth (11) . The tumor stem cells are potentially more resistant to cytotoxic therapies and may be molecularly distinct from the bulk of the tumor cells (12) . Most cell culture models of carcinogenesis have used differentiated cells or wellestablished cancer cell lines to investigate the properties of oncogenes, tumor suppressor genes, or to identify novel cancer drug targets (13) . However, if the cancer stem cell hypothesis is correct, then the most appropriate cells in which to investigate the genes involved in carcinogenesis may be stem cells. To this end, we have generated transformed human adult mesenchymal stem cells (MSC) using a stepwise introduction of five genetic hits including hTERT, inactivation of p53 and pRb, introduction of small T antigen to inactivate PP2A leading to stabilization of c-Myc, and finally introduction of H-Ras (14) . We have shown that MSC require the same number of genetic hits (five) as differentiated cells to become fully transformed (tumor formation in athymic mice).
We hypothesize that the enzymes specifically upregulated in the transformed MSC model will also be up-regulated in various sarcomas and carcinomas and may provide novel targets for cancer drug development. In this study, we have taken a forward genomics approach for drug target discovery by mining gene expression data from numerous cancer microarray data sets. Due to the current interest in enzymes for drug targets, we have focused here on identifying novel enzymes as candidate cancer drug targets. This transformed primary stem cell model also provides an excellent resource for in vitro validation of any identified therapeutic targets or to test novel drugs in the early stages of stepwise oncogenic transformation.
Materials and Methods

Enzyme Data Set
We identified all known enzymes in the human genome using the Expasy Enzyme database 3 August 21, 2007 release, which categorizes human enzymes into 207 oxidoreductases (EC 1), 319 transferases (EC 2), 300 hydrolases (EC 3), 63 lyases (EC 4), 33 isomerases (EC 5), and 73 ligases (EC 6). These f1,000 enzymes are represented by 2,256 probe sets from the Affymetrix hgu133plus2 genechips. For this study, we have not included candidate enzymes that do not have an EC number.
Gene Expression Microarray Data
We have used our transformed MSC cancer model Gene Expression Microarray data as a primary screen for upregulation of enzymes during transformation using a cutoff of 2-fold up-regulation (P < 0.05; ref. 14) . Extensive quantitative reverse transcription-PCR (qRT-PCR) validation of the data set has been done previously, and further details and quality-control measures can be found in the ArrayExpress database 4 with the accession no. E-MEXP-563 (14) .
The carcinoma expression data were downloaded from the expO public repository 5 by way of the National Center for Biotechnology Information Gene Expression Omnibus database. 6 We selected 146 samples hybridized to Affymetrix hgu133plus2 genechips, covering 11 common types of carcinoma (breast, colon, endometrium, kidney clearcell carcinoma, kidney papillary carcinoma, lung adenocarcinoma, ovary, prostate, rectum, thyroid, and bladder) with no fewer than 10 of each type. Our mesenchymal tumor expression data represent 19 different subtypes, including alveolar rhabdomyosarcoma, chondroblastoma, chondrosarcoma, chordoma, chondromyxoid fibroma, dedifferentiated chondrosarcoma, embryonal rhabdomyosarcoma, Ewing's sarcoma, fibromatosis, lipoma, leiomyosarcoma, myxoid liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor, neurofibroma, osteosarcoma, pleiomorphic sarcoma, schwannoma, and well-differentiated liposarcoma (15) . Raw CEL file data were processed and normalized to produce expression profiles using the ''rma'' algorithm. Cancer versus normal tissue control gene expression data were identified employing the Oncomine Web resource 7 using the differential expression function with a P cutoff of <0.0001 (Supplementary Table) . 8 Oncomine uses a data analysis method, whereby all data are log-transformed, median-centered per array, and SD-normalized to 1 per array. All tumor array data are described in Supplementary Tables S2 to S4. 8 Hierarchical clustering of MSC transformation gene expression data was done using DNA-Chip Analyzer (dChip). 9 Using a distance metric of 1-correlation and a centroid linkage method, significant clusters were identified with a P cutoff of <0.001. Further significance of clusters was done using the R package ''pvclust,'' which computes an approximate unbiased P value for clusters using a multiscale bootstrap resampling method (16) . pvclust was done with both n = 1,000 and n = 10,000 bootstrap with similar results (Supplementary Fig. S1 ). 8 Significant clusters were identified with P < 0.05.
qRT-PCR qRT-PCR was done on an Eppendorf Mastercycler using the following primer pairs: PPAP2C_F (5 ¶-ctgtatgtgcaggcacgact-3 ¶) and PPAP2C_R (5 ¶-aaaggccaccaggaagaact-3 ¶), RNA-SEH2A_F (5 ¶-ccagaccatcctggagaaag-3 ¶) and RNASEH2A_R 3 Expasy (http://www.expasy.ch/enzyme/). 4 ArrayExpress (http://www.ebi.ac.uk/microarray-as/aer/). 5 expO repository (https://expo.intgen.org/geo/home.do). 6 National Center for Biotechnology Information Gene Expression Omnibus (ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/SeriesMatrix/GSE2109). 7 Oncomine (http://www.oncomine.org). 8 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). 9 dchip (www.dchip.org).
(5 ¶-tgagtccctcctgattctcg-3 ¶), ADARB1_F (5 ¶-gtccgactcgaccatgactt-3 ¶) and ADARB1_R (5 ¶-tgccagagacaggaggattt-3 ¶), and GAPDH_F (5 ¶-ggagtcaacggatttggtcgta-3 ¶) and GAPDH_R (5 ¶-ggcaacaatatccactttaccagagt-3 ¶). The reaction mix contained 1Â SYBR Green master mix (Applied Biosystems) and 0.5 mmol/L of each forward and reverse primers in a volume of 30 AL. PCR cycling consisted of 95jC for 10 min and then 40 cycles of 95jC for 30 s, 60jC for 60 s followed by a melt-curve analysis. Fold change in expression was calculated by DDC t normalized to GAPDH for each sample and normalizing each of the cell lines to the average of the control cells: parental MSC (MSC 0), primary human fibroblasts (HF 0), or transformed MSC (MSC 5).
Cell Culture Primary MSC and each line containing a different set of oncogenes (see Fig. 1 ) were grown in Mesencult medium containing 10% human serum (Stem Cell Technologies) and 1 ng/mL basic fibroblast growth factor (R&D Systems). The primary human dermal fibroblasts (HF 0), immortalized human dermal fibroblasts (HF 1), transformed human dermal fibroblasts (HF 5), breast cancer cell line MCF7, leiomyosarcoma cell line SK-LMS1, and osteosarcoma cell lines MG63 and U2OS were cultured in DMEM containing 10% fetal bovine serum (Life Technologies/Invitrogen).
siRNA/shRNA Knockdown and In vitro Assays Knockdown was done by transfection with a pool of four siRNA oligonucleotides (100 nmol/L final concentration; Dharmacon) for each gene: RNASEH2A, ADARB1, and PPAP2C or ON-TARGETplus Nontargeting Control. Four individual siRNA oligonucleotides were also used for PPAP2C knockdown. Transfection was done using Oligofectamine reagent (Invitrogen) and the manufacturer's 14 for more details). The parental MSC was immortalized with hTERT (MSC 1hit); then, pRb and p53 were inactivated by addition of the human papillomavirus proteins E7 (MSC 2 hits) and E6 (MSC 3 hits) followed by inactivation of PP2A and stabilization of c-Myc by the addition of SV40 small T antigen (MSC 4 hits); finally, constitutively active H-Ras was expressed (MSC 5 hits). Enzymes that showed statistically significant >2-fold increase in expression in MSC 5 hits compared to parental MSC were selected and hierarchical clustering was done using dChip as described in Materials and Methods. Positive control enzymes (c) described in Fig. 2 protocol. Additional knockdown of RNASEH2A was done by transfection of shRNA vectors for RNASEH2A, nonsilencing control, and vector control from the Open Biosystems whole-genome pGIPZ shRNA library using FuGene reagent (Roche) and the manufacturer's protocol. Transfection efficiency of shRNA vectors was estimated at f30% by monitoring green fluorescent protein from the vector. Following transfection, the cells were grown for 48 h before harvesting for qRT-PCR or in vitro assays. Cell proliferation and viability was determined using the CellTiter 96 Aqueous One solution (Promega). Cells were plated in triplicate at 1,000 cells per well of a 96-well plate. The CellTiter solution was added at both 0 and 48 h time points using 30 AL/well and further incubated for 2 h at 37jC, and the absorbance was read at 490 nm to quantify the formazan product. Anchorage-independent growth was assessed by soft-agarose assays as described previously (14) . For cell cycle analysis, MCF7 cells were transfected with siRNA control pool or PPAP2C siRNA and grown for 48 h followed by serum starvation for 24 h to synchronize cells in G 1 phase. Cells were analyzed at 8 and 24 h postserum release to assess S-phase progression. Cells were harvested and fixed in 70% ethanol at 0jC, and the nuclear DNA was stained using a solution of propidium iodide (50 mg/mL), RNase A (1 mg/mL), and Triton X-100 (0.02%) in PBS. Cell suspensions were analyzed on a FACSCalibur (Becton Dickinson) using CellQuest and Modfit data analysis software.
Western Blot Antibodies used in this study include sc-126 (DO-1) for p53 (Santa Cruz Biotechnology) and Ab-1 for actin (Oncogene). 
Other Online Resources
We screened for novelty of targets using Entrez Gene 10 and PubMed 11 and identification of known drug targets from PharmGKB, 12 Thomson Pharma, 13 and Therapeutic Target Database.
14 Patent information was screened using esp@cenet 15 and Patent Lens. 16 
Results
Expression of Enzymes in the Transformed MSC Model
We analyzed the expression of all known enzymes in the human genome, with the aim of identifying novel enzymes that are up-regulated in transformed MSC, and not in primary MSC, and also in various cancers. Such enzymes could potentially be considered as new targets for cancer drug development. We identified 56 probe sets, representing 44 enzymes (one or two probe sets per gene), which are significantly up-regulated >2-fold (false discovery ratecorrected P < 0.05) in the transformed MSC (5 hits, MSC 5) compared with the primary MSC (0 hits, MSC 0; Fig. 1 ). Hierarchical clustering analysis of each of these probe sets identifies four significant (P < 0.05) clusters that stratify with the genetic alterations during stepwise transformation ( Supplementary Fig. S1 ). 8 The first cluster includes 4 enzymes (UPP1, XDH, MMP3, and CPE) up-regulated only after the fifth oncogenic hit, correlating with activation of the Ras pathway (constitutively active H-Ras) and the fully transformed state. The second major cluster contains 22 enzymes (from GCDH to RNMT) significantly increased after the inactivation of PP2A and stabilization of c-Myc (fourth hit), and a third cluster contains 17 enzymes (from GPD2 to MTAP), which are significantly up-regulated after the inactivation of pRb. The fourth cluster contains 4 enzymes (PTGS2, OAS1, NP, and PRSS3) and displays an interesting profile being up-regulated after introduction of hTERT (first hit) or p53 (third hit) suppression but then down-regulated after the inactivation of PP2A (fourth hit) and again increasing on H-Ras activation. We have shown previously that these clusters are representative of genes known to be transcriptionally regulated by each oncogenic hit ( Supplementary Fig. S6  8 in ref. 14) . Furthermore, as an example, we show that gene set enrichment analysis identifies a significant overrepresentation of known Myc targets (P = 0.009262) in the genes significantly upregulated or down-regulated after the fourth hit (17) .
Identification of Known CancerTargets
The majority of significantly up-regulated enzymes (32 of 44, 73%) in the transformed MSC either are already wellknown cancer drug targets, act within known drug pathways, or are current research targets previously identified as up-regulated in various malignancies (Table 1; Supplementary Table S1 ). 8 This is confirmed statistically in comparison with the percentage of known target enzymes in those that do not change expression in this model (12% are known targets) or are significantly down-regulated (11% are known targets; P = 8.425e-08, m 2 test). This can be considered as a positive control for the identification of candidate drug targets in this model and suggests that there may be few truly novel up-regulated enzymes in this model system left to be identified as cancer drug targets. We have identified four examples of well-characterized cancer drug targets that are also identified as significantly up-regulated in our transformed MSC cells: PTGS2 (cyclooxygenase-2), MMP1 and MMP3, and DHFR. Analysis of the expression of these candidates in the transformed MSC and in various cancer gene expression data sets reveals novel insights into the regulation of these genes and other enzymes with similar expression profiles ( Fig. 1) and also identifies novel cancers in which these genes are overexpressed ( Fig. 2A; Supplementary Fig. S2 ). 8 As an example, we show that hTERT alone is capable of up-regulating transcription of PTGS2 in MSC with a 1.8-fold increase (P = 0.039) compared with parental MSC. Furthermore, we observe increased expression of PTGS2 in seminoma, chondromyxoid fibroma, and malignant peripheral nerve sheath tumor, which have not been reported previously.
Structural Analysis of Druggable Enzymes
A structural analysis of all known genes has been done previously to identify the ''druggable genome,'' that is, proteins that contain structural elements amenable to small-molecule inhibition (3, 4) . A comparison of the upregulated enzymes in the MSC model and the druggable proteins identified 16 enzymes that are already targeted by specific drugs (ODC1, MME, NP, ALDH1A3, ADCY3, RRM1, ASNS, PPAT, UMPS, SOAT1, XDH, DHFR, DPYD, MMP3, MMP1, and PTGS2). In addition, we have also identified 4 enzymes that have been characterized as druggable and are up-regulated in numerous cancers, although no drugs have yet been developed against these targets (MTAP, PRSS3, CPE, and CTSH; Supplementary  Fig. S3 ). 8 These 4 enzymes have been implicated previously in cancer and thus cannot be considered novel candidates (18 -21) .
Identification of Novel CancerTargets
Novelty of candidate enzymes was investigated using several measures (Table 1) . GeneRifs or ''Gene Reference into Function'' consist of phrases taken from publications describing a function of the gene or association with particular diseases or cancers. The number of PubMed citations for particular genes also serves as a measure of how well characterized it is, and a systematic search of the literature on PubMed was used to identify any known associations with cancers. Finally, PharmGKB, Therapeutic Target Database, Thomson Pharma, and Patent databases indicate whether the gene is already a target of a known drug or acts within a known drug pathway. Specifically, if the gene is listed on any of the Web sites as a drug target, then we have considered that as a known target. Additionally, if the gene is within a very well described pathway, such as the methotrexate pathway ( Supplementary Fig. S4 ), 8 then we have also considered this a known target. Taken together, these measures have identified 3 enzymes (RNASEH2A, ADARB1, and PPAP2C), which are expressed in various malignancies, up-regulated in some cancers compared with normal tissues, and are candidate novel cancer targets (Table 1 ; Fig. 2) .
RNASEH2A is the catalytic subunit of the RNase H2 complex, which is the major source of RNase H activity in mammalian cells (22) , and is up-regulated in MSC after the inactivation of pRb and also in fully transformed MSC. It is also up-regulated in a variety of different cancer types including bladder, brain (glioblastoma multiforme, oligodendroglioma, and oligoastrocytoma), breast, head, and neck squamous cell carcinomas as well as leukemias (T-and B-cell acute lymphoblastic leukemia and acute myeloid leukemia), melanomas, and seminomas (Fig. 2B) . It is expressed in all of the carcinomas and sarcomas investigated with the highest expression observed in breast carcinomas and dedifferentiated chondrosarcomas, respectively. RNASEH2A was also one of the top 2% of genes (ranked 0.9845) identified by Mayburd et al. that showed significant correlation with the profiles of all known successful cancer drug targets (5).
PPAP2C is a member of the phosphatidic acid phosphatase family of enzymes (also known as lipid phosphate phosphatases) that regulate the dephosphorylation of lipid phosphates (23) . Compared with matched normal tissues, PPAP2C is significantly overexpressed in ovarian carcinoma similarly to other family members (ref. 24 ; Fig. 2C ). However, our analysis has shown that it is also overexpressed in bladder, lung, and prostate cancers compared with normal tissues. In the cancer gene expression data, we detect expression of PPAP2C in all carcinomas and sarcomas and it appears to be particularly highly expressed in breast carcinoma, dedifferentiated chondrosarcoma, fibromatosis, synovial sarcoma, and neurofibroma. PPAP2C is also significantly overexpressed in high-grade breast tumors compared with low-grade tumors ( Supplementary Fig. S5 ). 
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Adenosine deaminase is a key degradative enzyme of purine metabolism and is crucial for DNA replication and several purine nucleoside analogues have been developed to specifically target adenosine deaminase, including pentostatin and cladribine (Thomson Pharma Web site 10 ). There are, however, nine other members of the adenosine deaminase family in the human genome, many of which are RNA-specific including ADARB1, one of the candidates identified by our analysis. ADARB1 shows significant upregulation in lymphomas and seminomas in comparison with normal tissues and is expressed consistently in most carcinomas and sarcomas that we have investigated (Fig. 2D) . Of note is the significantly increased expression in chondromyxoid fibromas (CMF), a benign cartilaginous bone tumor, compared with all other sarcomas. The regulation of ADARB1 has not been described. We detect significant 5-fold increase in expression of ADARB1 in the gene expression microarray data (Fig. 1) and by qRT-PCR (data not shown) following the addition of small T antigen, which stabilizes the c-Myc oncogene, suggesting that Myc may be involved in transcriptional regulation of this enzyme.
Validation of Novel CancerTargets
We have confirmed the increased expression of RNA-SEH2A (4.8-fold; P = 0.012), ADARB1 (6.3-fold; P = 0.0002), and PAPP2C (7.7-fold; P = 0.0014) by qRT-PCR in the transformed MSC (MSC 5 hits) compared with the parental cells (Fig. 3A) . We have also sought to confirm the overexpression of these enzymes in transformed human fibroblasts, which may be more representative of carcinomas. These primary human fibroblasts were transformed with the same five oncogenic hits as were used in the MSC and showed similar signs of transformation including the ability to form colonies in soft agarose and tumors in athymic mice (14) . In the transformed fibroblasts, significant overexpression was detected for both RNASEH2A (2.0-fold; P = 0.0058) and PPAP2C (6.2-fold; P = 0.00065) compared with the primary fibroblasts. However, ADARB1 was not significantly different to the parental fibroblasts (Fig. 3B) .
Expression was also confirmed in each of the cancer cell lines tested with similar expression levels to the transformed MSC and significantly lower expression in the two normal cell lines (Fig. 3C) .
We have investigated the role of RNASEH2A, PPAP2C, and ADARB1 in proliferation and transformation by siRNA knockdown in the transformed MSC, transformed human fibroblasts, and the cancer cell lines MCF7 (breast cancer), SK-LMS1 (leiomyosarcoma), MG63 (osteosarcoma), and U2OS (osteosarcoma). We compared the cell viability results in cancer cells with the immortalized normal cell lines MSC 1 (MSC + hTERT) and HF 1 (human fibroblasts + hTERT; Fig. 4) . Knockdown for each of the genes was confirmed by qRT-PCR analysis of mRNA levels in each of the cell lines tested (Supplementary Fig. S6 ).
8 siRNA knockdown of RNASEH2A or ADARB1 significantly altered the cell viability of one osteosarcoma cell line, U2OS; however, neither gene altered the proliferation of any of the other cell lines tested. Knockdown of PPAP2C significantly decreased the cell viability of all cancer cell lines tested, except the leiomyosarcoma cell line SK-LMS1. In the normal immortalized MSC and fibroblasts, inhibition of RNASEH2A and ADARB1 did not alter cell viability; however, PPAP2C knockdown altered the viability of the MSC but not the differentiated fibroblasts (Fig. 4A) . The sequence specificity of PPAP2C knockdown by the pooled siRNA oligonucleotides was confirmed by knocking down expression with the four oligonucleotides separately in the transformed fibroblasts compared with the normal fibroblasts (Fig. 4B) .
We have shown previously that transformed MSC form colonies rapidly in soft agarose similarly to many cancer qRT-PCR was done for ADARB1, RNASEH2A, and PPAP2C in the transformed MSC (MSC 5) compared with the parental MSC (MSC 0) (A) and in human dermal fibroblasts (HF 0) compared with transformed human dermal fibroblasts (HF 5) (B). Fold change in expression was calculated in three replicates by DDC t normalized to GAPDH for each sample and normalizing each of the cell lines to the average of the parental cells. Student's t test was done for statistical analysis. C, expression of RNASEH2A, PPAP2C, and ADARB1 in cancer cell lines was calculated in three replicates by DDC t normalized to GAPDH for each sample and normalizing each of the cell lines to the average of the transformed MSC for each of the genes separately.
cell lines (14) . The transient siRNA or shRNA knockdown of RNASEH2A in transformed MSC significantly reduced the number of colonies formed in soft agarose (Fig. 4C  and D) . This finding was also observed in transformed fibroblasts HF 5, MCF7, SK-LMS1, and MG63. The osteosarcoma cell line U2OS and the immortalized MSC and fibroblasts do not form colonies in soft agarose. This is the first evidence that RNASEH2A may play a role in transformation. Although ADARB1 knockdown suppressed soft-agarose colony formation in transformed MSC, we did not observe a similar result in any other cell line.
In rat fibroblasts, the homologous gene, Ppap2c, caused a premature entry into S phase when overexpressed and delayed S-phase entry when knocked down (25) . We have confirmed this in the human breast cancer cell line, MCF7, which expresses the highest level of PPAP2C and showed a high degree of inhibition of in vitro proliferation. We show that PPAP2C siRNA knockdown in MCF7 delays S-phase progression and does not induce apoptosis (Fig. 5A) . Furthermore, we show that PPAP2C is up-regulated in the transformed MSC model after the addition of human papillomavirus E6 (which suppresses p53 function) and is also up-regulated following shRNA knockdown of p53 or overexpression of a dominant-negative form of p53 (Fig.  5B-D) . These data are consistent with a role for p53 in the transcriptional regulation of PPAP2C.
Discussion
In this study, we have sought to identify novel cancer drug targets by investigating a transformed MSC model. This model represents the oncogenic alterations that occur in the transformation process and the transcriptional changes observed are specific to each oncogenic hit in a homogenous cell type. We use this model in addition to studying tumor tissue compared with normal tissue, which represent the molecular alterations that have occurred late in the tumor development (at the time of diagnosis and surgical resection of the tumor) and in a heterogeneous cell population.
The approach that we have taken in this study provides an excellent resource for investigating the regulation and expression of established successful drug targets, as we have shown that many of these enzymes are up-regulated in this model. We have elaborated on four of these targets, PTGS2, DHFR, MMP1, and MMP3, which we observe are up-regulated in numerous cancer types and serve as a benchmark for the novel targets that we have also identified. Despite the cardiovascular side effects of one inhibitor (Vioxx), PTGS2 inhibitors (coxibs) are currently in clinical trials for various malignancies including colorectal, non-small cell lung, breast, prostate, and pancreatic cancers (26 -28) . PTGS2 was shown previously to be overexpressed in chordoma and chondrosarcoma; however, the use of coxibs for sarcomas has yet to be explored (29, 30) . Our analysis identified several novel cancers in which PTGS2 appears to be overexpressed including the difficult-to-treat sarcomas, chondromyxoid fibroma, and malignant peripheral nerve sheath tumor. These data provide evidence that coxibs could be worth investigating in these tumor types and suggest novel indications for these drugs. Methotrexate is one of the first clinically useful broad-range antimetabolic anticancer drugs that targets DHFR (31) . It is a drug that has been used for numerous cancer types and it is encouraging to see that the MSC model includes not only up-regulation of DHFR but also many other enzymes involved in the de novo purine biosynthesis pathway ( Supplementary Fig. S6 ). 8 The MMP gene family including MMP1 and MMP3 are also recognized as pharmaceutical targets (32) . The challenge ahead for this class of drugs appears to be in the development of specific active sitedirected inhibitors against specific MMPs (32) . Although our analysis has confirmed the overexpression of these genes in many cancers, we have also identified several novel tumors that express MMP1 (chondroblastoma) and MMP3 (chordoma and seminoma), suggesting that the full range of malignancies that the drugs against these targets could be used for is yet to be explored ( Supplementary  Fig. S2 ). 8 Similarly to these known targets, the novel enzymes that we have identified, RNASH2A, PPAP2C, and ADARB1, are overexpressed in numerous cancer types and targeting these genes could have potentially broad therapeutic options.
The lysophosphatidic acid signaling cascade may be a novel target for therapy in ovarian cancer (24) . Indeed, targeting the lipid signaling cascade is an emerging therapeutic strategy for cancer, inflammation, and metabolic diseases (33) . Furthermore, phosphatidic acid phosphatase enzymes are involved in receptor-activated signal transduction by the phospholipase D enzyme family, which are key requirements for Ras-mediated transformation (34) . Our data suggest that overexpression of PPAP2C, observed in numerous human cancers, may be a requirement for increased cell proliferation. It is, therefore, not unexpected that its regulation is controlled in part by p53, which is known to suppress many other cell cycle regulating genes such as chk1, cdc20, cdc25A, and cdc25c (35) . Our data also show that the normal MSC are inhibited by the knockdown of PPAP2C, whereas the differentiated cells are not affected despite the similar expression levels. We suggest that this is due to a common feature shared by both the cancer cell lines and the normal stem cells, which could be the ability for self-renewal or an increased susceptibility to aberrant cell cycle signals. This particular enzyme family could be attractive targets as they are expressed on the plasma membrane, with the active site facing the extracellular matrix potentially allowing recognition by therapeutic antibodies.
The RNase H2 complex is a heterotrimer composed of the catalytic subunit RNASEH2A and the noncatalytic subunits RNASEH2B and RNASEH2C, which together are able to recognize and cleave a single ribonucleotide embedded in a DNA-DNA complex (36) . This complex also mediates the excision of single ribonucleotides from DNA:RNA duplexes such as in the removal of the lagging-strand Okazaki fragment RNA primers during DNA replication (37) . Thus, a plausible biological hypothesis for this gene as a candidate drug target is likely to involve its role in DNA replication. It is now apparent that the role of RNA in the cell includes regulation of gene expression via RNA interference pathways, heterochromatin formation, and targeting DNA methylation and histone modifications (38, 39) . RNA regulating enzymes, therefore, could represent a novel class of enzymes that could be considered as potential cancer drug targets. Inactivating mutations in the three RNase H2 subunits have recently been implicated in the autosomal recessive neurologic disorder AicardiGoutières syndrome (36) . If RNASEH2A is involved in transformation as suggested by our data, it would be interesting to further investigate whether heterozygous carriers of these Aicardi-Goutières syndrome mutations are to a certain extent protected against cancer.
ADARB1 is an RNA-specific adenosine deaminase, which encodes an enzyme that is responsible for premRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines (40) . Although we detect no adverse effects of ADARB1 knockdown in the cancer cell lines tested, the role of RNA editing may play a role in brain tumor formation (41, 42) . This has been described as an epigenetic mechanism and may also help or hinder miRNA functions by editing to interfere with pri-mRNA processing, altering target sites, or editing of miRNA sequences themselves (42) .
In conclusion, the in silico approach investigating all known enzymes in a transformed stem cell model is a useful approach that could equally be applied to investigate all G protein-coupled receptors, ion channel genes, or putative enzymes. In addition to identifying novel candidate cancer targets, this genetic approach can also improve current drug therapy in humans by identifying novel cancers in which known targets are up-regulated and provide further insight into the oncogenic regulation of these known targets. We have identified three enzymes, RNASEH2A, PPAP2C, and ADARB1, which, to our knowledge, are novel putative candidate cancer drug targets. We have confirmed the overexpression in cancer cell lines and have shown that inhibition of two of these candidates, RNASEH2A and PPAP2C, leads to a reduction in the in vitro proliferation or transformation of cancer cells. This suggests that our analytical screen, combining both our in vitro model and public gene expression data, may have enriched for genes that alter the proliferation of cancer cells. However, the extent to which this analysis has enriched for true drug targets can only be determined with additional screening of more genes compared with a variety of genes that were not hits in this screen. Both of these identified genes could be classified as ''non-oncogene addiction'' genes that are required for continued cancer cell proliferation but not essential for normal differentiated cell proliferation. This category of genes is the most desirable for targeting for cancer therapy (10) . However, validation of these genes as true cancer targets can only be claimed once a therapeutic agent is developed and shown to be clinically effective by acting against the target to which it was designed (43) . 
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